(R)-CR8
CAS No. 294646-77-8
(R)-CR8 ( CR8 ,(R)-Isomer )
Catalog No. M22098 CAS No. 294646-77-8
(R)-CR8 is a potent and selective CDK inhibitor.A delayed systemic post-LFP administration at 3 hours of CR8--a potent second-generation cyclin-dependent kinase (CDK) inhibitor.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
5MG | 405 | In Stock |
|
10MG | 597 | In Stock |
|
25MG | 888 | In Stock |
|
50MG | 1251 | In Stock |
|
100MG | 1692 | In Stock |
|
200MG | Get Quote | In Stock |
|
500MG | Get Quote | In Stock |
|
1G | Get Quote | In Stock |
|
Biological Information
-
Product Name(R)-CR8
-
NoteResearch use only, not for human use.
-
Brief Description(R)-CR8 is a potent and selective CDK inhibitor.A delayed systemic post-LFP administration at 3 hours of CR8--a potent second-generation cyclin-dependent kinase (CDK) inhibitor.
-
Description(R)-CR8 is a potent and selective CDK inhibitor.A delayed systemic post-LFP administration at 3 hours of CR8--a potent second-generation cyclin-dependent kinase (CDK) inhibitor--reduced CCA;?cortical, hippocampal, and thalamic neuronal loss;?and cortical microglial and astrocyte activation.?Furthermore, CR8 treatment attenuated sensorimotor and cognitive deficits, alleviated depressive-like symptoms, and decreased lesion volume.
-
SynonymsCR8 ,(R)-Isomer
-
PathwayAngiogenesis
-
TargetCDK
-
RecptorCDK
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number294646-77-8
-
Formula Weight431.53
-
Molecular FormulaC24H29N7O
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCC[C@H](CO)Nc1nc(NCc2ccc(cc2)-c2ccccn2)c2ncn(C(C)C)c2n1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Kabadi SV, et al. CR8, a novel inhibitor of CDK, limits microglial activation, astrocytosis, neuronal loss, and neurologic dysfunction after experimental traumatic brain injury. J Cereb Blood Flow Metab. 2014 Mar;34(3):502-13.
molnova catalog
related products
-
Amt-87
Amt-87 is a HIV latency-reversal agent that reactivates latent HIV at the transcriptional level, promotes phosphorylation of CDK9 T-loop at Thr186.
-
PNU-112455A
PNU-112455A is an ATP-competitive CDK2/5 inhibitor with Ki of 2 uM and 2 uM for cdk2·GST-cyclin E and cdk5·GST-p25 respectively.
-
GW-8510
GW-8510 (GW8510) is apotent, selective inhibitor of CDK2 with IC50 of 10 nM; displays weak inhibition for CDK1 and CDK4 (IC50=110 and 130 nM, respectively) in vitro biochemical assays.